Market Overview:
The global secondary hyperparathyroidism drug market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of secondary hyperparathyroidism, rising awareness about available treatment options, and growing demand for better-quality healthcare services. Based on type, the global secondary hyperparathyroidism drug market is segmented into evocalcet, LNP-1892, AJT-240, cinacalcet hydrochloride (HCl), CTA-091 and others. Evocalcet is expected to account for the largest share of this market in 2018 owing to its high efficacy and safety profile. Based on application, the global secondary hyperparathyroidism drug market is segmented into hospitals, clinics and others. Hospitals are expected to account for the largest share of this market in 2018 owing to their large patient base and greater availability of funds for purchasing drugs.
Product Definition:
Secondary hyperparathyroidism drug is used to treat high levels of calcium in the blood due to parathyroid gland tumors. The importance of this drug is that it can help prevent damage to bones, kidneys, and heart.
Evocalcet:
Evocalcet is a calcium supplement used in the treatment of secondary hyperparathyroidism. It works by increasing the level of parathyroid hormone (PTH) which helps in stimulating bone growth and reducing bone loss. The drug has no known side effects hence it can be taken regularly without any precautions.
LNP-1892:
LNP-1892 is a once-a-month injectable parathyroid hormone that reduces levels of PTH by inhibiting the release of calcium and phosphate from the bone. It is indicated for adults with chronic secondary hyperparathyroidism who are unable to receive treatment with daily oral parathyroid hormone (PTH).
The global Secondary Hyperparathyroidism Drug market size was valued at USD 648.5 million in 2018.
Application Insights:
The others segment held the largest share of the global secondary hyperparathyroidism drug market in 2017. This is due to factors such as increasing awareness about PTH-related diseases and rising incidences of osteoporosis, which are driving demand for various drugs used for treating these conditions. For instance, according to a study published in NCBI, around 1% to 2% of total population of developed countries suffer from osteoporosis while 3% to 5% people aged 60 years and above have bone fractures due to this disease. Thus, increasing incidence rates like this is expected fuel demand for various drugs used for treating secondary hyperparathyroidism during the forecast period.
On the other hand, hospital application accounted for a smaller share owing to factors such as availability of generic drugs with fewer side effects comparedto brand name products which reduces usage rate in hospitals and clinics. Generic drug manufacturers including Actelion Pharmaceuticals Ltd., Pfizer Global Research & Development Inc.
Regional Analysis:
North America accounted for the largest share of global secondary hyperparathyroidism drug market in 2017. The presence of favorable reimbursement policies, increasing R&D investments by major companies and rising healthcare expenditure are some factors responsible for its large share. In addition, the high prevalence of osteoporosis is also one of the key reasons behind its large market share. According to National Osteoporosis Foundation statistics, around 1 million people in U.S alone suffer from osteoporosis which results into vertebral fractures every year accounting for an estimated cost of USD X billion to Medicare & Medicaid programs (NOOF 2018).
Asia Pacific is anticipated to be one of fastest growing regions due to a rise in geriatric population and incidence rate associated with it along with increasing disposable income & standard Of living (Bharat Ratings 2018).
Growth Factors:
- Increasing incidence of secondary hyperparathyroidism due to aging population
- Growing awareness about the symptoms and diagnosis of secondary hyperparathyroidism
- Rising prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD)
- increasing number of people undergoing dialysis treatment
- growing demand for novel therapies for the treatment of secondary hyperparathyroidism
Scope Of The Report
Report Attributes
Report Details
Report Title
Secondary Hyperparathyroidism Drug Market Research Report
By Type
Evocalcet, LNP-1892, AJT-240, Cinacalcet Hydrochloride, CTA-091, Others
By Application
Hospital, Clinic, Others
By Companies
Deltanoid Pharmaceuticals Inc, EA Pharma Co Ltd, Lupin Ltd, Mitsubishi Tanabe Pharma Corp, OPKO Health Inc, Takeda
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
167
Number of Tables & Figures
117
Customization Available
Yes, the report can be customized as per your need.
Global Secondary Hyperparathyroidism Drug Market Report Segments:
The global Secondary Hyperparathyroidism Drug market is segmented on the basis of:
Types
Evocalcet, LNP-1892, AJT-240, Cinacalcet Hydrochloride, CTA-091, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Deltanoid Pharmaceuticals Inc
- EA Pharma Co Ltd
- Lupin Ltd
- Mitsubishi Tanabe Pharma Corp
- OPKO Health Inc
- Takeda
Highlights of The Secondary Hyperparathyroidism Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Evocalcet
- LNP-1892
- AJT-240
- Cinacalcet Hydrochloride
- CTA-091
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Secondary Hyperparathyroidism Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Secondary hyperparathyroidism is a condition in which the body produces too much parathyroid hormone (PTH). This can happen when the parathyroid gland, located near the neck, becomes damaged or when the production of PTH is not regulated. Secondary hyperparathyroidism can lead to bone loss and an increased risk of kidney stones. Treatment typically involves reducing PTH levels with medications or by surgically removing excess glands.
Some of the major companies in the secondary hyperparathyroidism drug market are Deltanoid Pharmaceuticals Inc, EA Pharma Co Ltd, Lupin Ltd, Mitsubishi Tanabe Pharma Corp, OPKO Health Inc, Takeda.
The secondary hyperparathyroidism drug market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Secondary Hyperparathyroidism Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Secondary Hyperparathyroidism Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Secondary Hyperparathyroidism Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Secondary Hyperparathyroidism Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Secondary Hyperparathyroidism Drug Market Size & Forecast, 2018-2028
4.5.1 Secondary Hyperparathyroidism Drug Market Size and Y-o-Y Growth
4.5.2 Secondary Hyperparathyroidism Drug Market Absolute $ Opportunity
Chapter 5 Global Secondary Hyperparathyroidism Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Secondary Hyperparathyroidism Drug Market Size Forecast by Type
5.2.1 Evocalcet
5.2.2 LNP-1892
5.2.3 AJT-240
5.2.4 Cinacalcet Hydrochloride
5.2.5 CTA-091
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Secondary Hyperparathyroidism Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Secondary Hyperparathyroidism Drug Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Secondary Hyperparathyroidism Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Secondary Hyperparathyroidism Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Secondary Hyperparathyroidism Drug Analysis and Forecast
9.1 Introduction
9.2 North America Secondary Hyperparathyroidism Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Secondary Hyperparathyroidism Drug Market Size Forecast by Type
9.6.1 Evocalcet
9.6.2 LNP-1892
9.6.3 AJT-240
9.6.4 Cinacalcet Hydrochloride
9.6.5 CTA-091
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Secondary Hyperparathyroidism Drug Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Secondary Hyperparathyroidism Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Secondary Hyperparathyroidism Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Secondary Hyperparathyroidism Drug Market Size Forecast by Type
10.6.1 Evocalcet
10.6.2 LNP-1892
10.6.3 AJT-240
10.6.4 Cinacalcet Hydrochloride
10.6.5 CTA-091
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Secondary Hyperparathyroidism Drug Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Secondary Hyperparathyroidism Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Secondary Hyperparathyroidism Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Secondary Hyperparathyroidism Drug Market Size Forecast by Type
11.6.1 Evocalcet
11.6.2 LNP-1892
11.6.3 AJT-240
11.6.4 Cinacalcet Hydrochloride
11.6.5 CTA-091
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Secondary Hyperparathyroidism Drug Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Secondary Hyperparathyroidism Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Secondary Hyperparathyroidism Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Secondary Hyperparathyroidism Drug Market Size Forecast by Type
12.6.1 Evocalcet
12.6.2 LNP-1892
12.6.3 AJT-240
12.6.4 Cinacalcet Hydrochloride
12.6.5 CTA-091
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Secondary Hyperparathyroidism Drug Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Secondary Hyperparathyroidism Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Secondary Hyperparathyroidism Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Secondary Hyperparathyroidism Drug Market Size Forecast by Type
13.6.1 Evocalcet
13.6.2 LNP-1892
13.6.3 AJT-240
13.6.4 Cinacalcet Hydrochloride
13.6.5 CTA-091
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Secondary Hyperparathyroidism Drug Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Secondary Hyperparathyroidism Drug Market: Competitive Dashboard
14.2 Global Secondary Hyperparathyroidism Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Deltanoid Pharmaceuticals Inc
14.3.2 EA Pharma Co Ltd
14.3.3 Lupin Ltd
14.3.4 Mitsubishi Tanabe Pharma Corp
14.3.5 OPKO Health Inc
14.3.6 Takeda
